Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Amgen’s Izervay NDA Accepted by NMPA for Geographic Atrophy Secondary to Age-Related Macular Degeneration

Fineline Cube May 15, 2026
Company Drug

Chongqing Genrix Bio Receives NMPA Clinical Approval for GR1803 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma

Fineline Cube May 15, 2026
Company Deals

Vivolight Medical Secures Over RMB 100 Million in Strategic Financing to Boost Global Expansion

Fineline Cube Mar 5, 2024

Shenzhen Vivolight Medical Device & Technology Co., Ltd, a Chinese medical device company nurtured and...

Company Drug

Huadong Medicine’s Arcalyst Filing for Recurrent Pericarditis Accepted by China’s NMPA

Fineline Cube Mar 5, 2024

Huadong Medicine Co., Ltd, (SHE: 000963) a Chinese pharmaceutical company, has announced that the National...

Company Medical Device

Sino Medical Sciences Receives Hong Kong Approval for HT Supreme Drug-Eluting Stent System

Fineline Cube Mar 5, 2024

Sino Medical Sciences Technology Inc., (SHA: 688108), a Chinese medical technology company, has announced that...

Company Drug

Hengrui Pharmaceuticals Gets NMPA Green Light for KRAS G12C Inhibitor Clinical Trial in Advanced Solid Tumors

Fineline Cube Mar 5, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received approval from the National Medical Products...

Company Drug

HitGen Secures CDE Approval for Lipisense IND Filing, Advancing Development for Dyslipidemia Treatment

Fineline Cube Mar 5, 2024

HitGen Inc., (SHA: 688222) a China-based pharmaceutical company, has announced that the Investigational New Drug...

Company Drug

ViiV Healthcare Presents Phase I Data for Ultra-Long-Acting Cabotegravir in HIV Treatment and Prevention

Fineline Cube Mar 5, 2024

GlaxoSmithKline (GSK; NYSE: GSK) unit ViiV Healthcare has presented Phase I results for an ultra-long-acting...

Company Deals

Merck Teams Up with C4 Therapeutics for Targeted Protein Degraders in Oncology

Fineline Cube Mar 5, 2024

Merck (NYSE: MRK), a Germany-headquartered science and technology company, has entered into a partnership with...

Company Digital

Innovent Biologics’ Taletrectinib Receives Second NDA Acceptance in China for ROS1 Positive NSCLC

Fineline Cube Mar 5, 2024

Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, has announced that the...

Company Drug

BMS Reports Positive Long-Term Data for Zeposia in Multiple Sclerosis Trials

Fineline Cube Mar 4, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) has unveiled results from several Phase III trials for...

Company Drug

BeiGene’s Brukinsa Outperforms Acalabrutinib in MAIC for Relapsed/Refractory CLL, Says BeiGene

Fineline Cube Mar 4, 2024

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the results of a matching-adjusted...

Company Drug

Merck’s Mavenclad Demonstrates Lasting Efficacy in RMS Patients, New Data Show

Fineline Cube Mar 4, 2024

Merck KGaA (ETR: MRK), a German multinational pharmaceutical, chemical, and life sciences company, has this...

Legal / IP

AlzeCure Pharma’s Alzheimer’s Drug Candidate ACD856 Receives Global Patent Awards

Fineline Cube Mar 4, 2024

AlzeCure Pharma, a Swedish pharmaceutical company, has announced the receipt of patent approval awards for...

Company Deals

Sino-Biocan Secures Series B Funding to Boost Cell and Gene Therapy Production Platforms

Fineline Cube Mar 4, 2024

Sino-Biocan (Shanghai) Biotech Ltd, a provider of automated, modularized, closed cell production platforms for the...

Company Drug

AIM Vaccine Advances Pneumococcal Vaccine and Initiates Phase II Meningococcal Study

Fineline Cube Mar 4, 2024

AIM Vaccine Co., Ltd (HKG: 6660) has delivered a series of updates on the development...

Company Deals

ArkBio Partners with SDODT to Boost ADHD Treatment Marketing and Commercialization

Fineline Cube Mar 4, 2024

Shanghai Ark Biopharmaceutical Co., Ltd (ArkBio), a Chinese biopharmaceutical company, has entered into a partnership...

Company Drug

Hainan Poly Pharm Secures Tentative FDA Approval for Generic Version of UCB’s Briviact

Fineline Cube Mar 4, 2024

Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, has announced that it...

Company Drug

BMS’s Yervoy-Opdivo Combo on Track for Breakthrough Therapy Designation in China for CRC

Fineline Cube Mar 4, 2024

The China Center for Drug Evaluation (CDE) website has indicated that the market approval filing...

Company Deals

Beijing Tinavi Medical Technologies to Form Radiotherapy Equipment JV with IM INNO and Celestial Oncology

Fineline Cube Mar 4, 2024

Beijing Tinavi Medical Technologies Co., Ltd (SHA: 688277) has announced its intention to establish a...

Company Drug

Pfizer’s RSV Vaccine Demonstrates Durable Efficacy with Abrysvo Phase III Results

Fineline Cube Mar 4, 2024

Pfizer Inc. (NYSE: PFE) last week reported the outcomes of a Phase III trial for...

Policy / Regulatory

Biden’s Executive Order May Restrict Data Access for China-Based Life Science Firms in the US

Fineline Cube Mar 4, 2024

US President Joe Biden last week issued an Executive Order titled “Preventing Access to Americans’...

Posts pagination

1 … 395 396 397 … 666

Recent updates

  • Alibaba Health Reports Strong FY2026 Results with 35.2% Profit Growth and Launches Medical LLM “H+”
  • Amgen’s Izervay NDA Accepted by NMPA for Geographic Atrophy Secondary to Age-Related Macular Degeneration
  • China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations
  • Chongqing Genrix Bio Receives NMPA Clinical Approval for GR1803 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma
  • AstraZeneca Reports Positive Phase III VOLGA Interim Results for Imfinzi-Based Combinations in Muscle-Invasive Bladder Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Digital

Alibaba Health Reports Strong FY2026 Results with 35.2% Profit Growth and Launches Medical LLM “H+”

Company Drug

Amgen’s Izervay NDA Accepted by NMPA for Geographic Atrophy Secondary to Age-Related Macular Degeneration

Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Company Drug

Chongqing Genrix Bio Receives NMPA Clinical Approval for GR1803 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.